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Blocks to thyroid cancer cell apoptosis can be
overcome by inhibition of the MAPK and PI3K/AKT
pathways
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4, P Vanden Borre
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1, R Khosravi-Far
2 and S Parangi*
,1
Current treatment for recurrent and aggressive/anaplastic thyroid cancers is ineffective. Novel targeted therapies aimed at the
inhibition of the mutated oncoprotein BRAF
V600E have shown promise in vivo and in vitro but do not result in cellular apoptosis.
TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a tumor-selective manner by activating the extrinsic
apoptotic pathway. Here, we show that a TRAIL-R2 agonist antibody, lexatumumab, induces apoptosis effectively in some
thyroid cancer cell lines (HTh-7, TPC-1 and BCPAP), while more aggressive anaplastic cell lines (8505c and SW1736) show
resistance. Treatment of the most resistant cell line, 8505c, using lexatumumab in combination with the BRAF
V600E inhibitor,
PLX4720, and the PI3K inhibitor, LY294002, (triple-drug combination) sensitizes the cells by triggering both the extrinsic and
intrinsic apoptotic pathways in vitro as well as 8505c orthotopic thyroid tumors in vivo. A decrease in anti-apoptotic proteins,
pAkt, Bcl-xL, Mcl-1 and c-FLIP, coupled with an increase in the activator proteins, Bax and Bim, results in an increase in the Bax
to Bcl-xL ratio that appears to be critical for sensitization and subsequent apoptosis of these resistant cells. Our results suggest
that targeting the death receptor pathway in thyroid cancer can be a promising strategy for inducing apoptosis in thyroid cancer
cells, althoughcombination with other kinase inhibitors may be needed insome of the more aggressive tumors initiallyresistant
to apoptosis.
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The incidence of well-differentiated thyroid cancers in United
States has increased dramatically in the past decade.
1
Patients with the most common type of thyroid cancer,
papillary thyroid cancer (PTC), have a low risk of recurrence
and high survival. However, a subset of patients with
anaplastic thyroid cancer (ATC) present with large invasive
tumors and/or metastases, do not respond to any chemother-
apeutic regimen and often die within months.
2 New data are
emerging on the genetic or epigenetic changes, which seem
to contribute to such dramatic worsening of the prognosis in
ATC compared with most other thyroid cancers.
3 Correlative
studies have pointed to increased incidence of mortality in
patients who have activating BRAF
V600E mutations
4–6 in the
mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated kinase (ERK) signaling pathway.
7,8 Therapeutics
blocking this signaling pathway are currently in clinical trials.
9
Although BRAF
V600E inhibitors work well in vitro in an anti-
proliferative and anti-invasive capacity and effectively reduce
tumorvolume invivo inanimalmodels,they arenotcapableof
inducing apoptosis in thyroid cancer cells.
10–12 Little is known
regarding the mechanisms underlying resistance to apoptosis
in these thyroid cancer cells. Here, we looked at using novel
apoptotic agents to increase thyroid tumor apoptosis by
activating the death receptor pathway and showed that in
some cases combination with anti-BRAF therapies is neces-
sary to fully activate apoptosis.
TNF-related apoptosis-inducing ligand (TRAIL) ligand is a
promising agent that induces apoptosis in a tumor-speciﬁc
manner by interacting with speciﬁc death domain receptors,
TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Activation of death
domain receptors induces formation of the intracellular
cytoplasmic Death-Inducing Signaling Complex (DISC),
which directly activates the extrinsic apoptotic pathway while
also crosstalking with the intrinsic pathway through Bid.
13,14
Lexatumumab (HGS-ETR2) is a fully humanized agonistic
monoclonal antibody that speciﬁcally activates the TRAIL-R2
and has never been tested in thyroid cancer in any capacity.
Lexatumumab is currently in phase I/II trials in advanced
malignancy. This antibody approach has several advantages
over the TRAIL ligand itself including improved pharmacoki-
netics and lack of decoy receptor binding,
15–17 although
some tumors exhibit resistance to apoptosis.
18 Resistance
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protein (c-FLIP),
19,20 reduced expression of TRAIL-R2 and
TRAIL-R1 receptors on tumor cell surface, overexpression of
anti-apoptoticproteins(Bcl-2,Bcl-xLandinhibitorsofapoptosis
(IAP) family members) and reduced expression of pro-
apoptotic proteins (Bax). Low Bax/Bcl-xL ratio has also been
shown to have a critical role in TRAIL resistance.
21–23
Lexatumumab has been combined with various drugs to
overcome resistance to apoptosis in a variety of tumors
in vitro and in vivo. These have included small molecule
inhibitors (lapatanib,
24 cycloheximide
25), chemotherapeutic
agents (cisplatin,
26 dacarbazine
27), antiangiogenic factors
(3TSR
18) and also PI3K and MAPK inhibitors.
28–31 However,
no studies of apoptosis with lexatumumab have been
performed in thyroid cancer.
Results
Some thyroid cancer cell lines showed exquisite sensi-
tivity to lexatumumab-induced apoptosis. Treatment with
lexatumumab (1000ng/ml) for 24h resulted in signiﬁcant
apoptosis in three of the ﬁve thyroid cancer cell lines.
Apoptosis was measured by annexinV/PE staining for the
percent of annexinV-positive cells. The cell lines TPC-1
(98.6.1±1.0%, Po0.001), HTh-7 (82.9±15.5%, Po0.001)
and BCPAP (82.6±22.3%, Po0.01) showed dramatically
higher percentage of apoptosis than the positive control, colon
cancer cell line HCT116
18 (38.9±4.6%, Po0.01; Figure 1a).
TPC-1 was the most sensitive to lexatumumab with an IC50 of
B194ng/ml followed by HTh-7 (B220.4ng/ml) and BCPAP
(B401.5ng/ml; Figure 1b). Lexatumumab-induced apoptosis
was conﬁrmed in all three sensitive cell lines by TUNEL
staining, cleavage of caspases-8/-9, the effector caspase-3
and PARP, thus demonstrating activation of both extrinsic and
intrinsic pathways. c-FLIP, the inhibitor of caspase-8,
decreased with lexatumumab treatment (Figures 1c and d).
All cell lines had functionally active TRAIL-R2 receptors, with
the highest levels present in these sensitive cell lines
(Figure 3c). At 8h there was a decrease in the TRAIL-R2
surface receptor after lexatumumab treatment, perhaps due to
the high rate of cell death. Normal thyroid cells, HTori, did not
undergo apoptosis with lexatumumab treatment (Figure 1a).
Lexatumumab inhibits BCPAP tumor growth in an
orthotropic mouse model. To evaluate whether the dra-
matic effect of lexatumumab observed in vitro would also
result in tumor volume reductions in vivo, we examined the
efﬁcacy of lexatumumab in mice bearing orthotopically
implanted BCPAP tumors. The BCPAP cell line was chosen
for in vivo testing because previous experiments in our
laboratory have shown that the other sensitive cell lines
(TPC-1, HTh-7) do not grow well in mice (unpublished data).
As previously described,
32 BCPAP cells were implanted into
the left thyroid lobe of SCID mice. Three weeks post
implantation when the tumor volume ranged from B30 to
40mm
3, treatment was started twice weekly for 4 weeks
total. Six of the mice were treated with intravenous (IV)
injections of lexatumumab antibody (10mg/kg body weight)
and six with saline (Figure 2a). Four weeks of lexatumumab
treatment signiﬁcantly reduced tumor volume from
204±42.5 to 66.5±26.7mm
3,( Po0.001), with a TGI of
67.4% (Figure 2b). Lexatumumab-treated tumors were TTF-
1-positive and showed signiﬁcantly higher percentage of
apoptotic cells by TUNEL and cleaved caspse-3 staining
compared with controls (14.59±2.16% versus 2.47±0.6%,
Po0.001; Figure 2c). Of note, there are no lung metastases
in this BCPAP orthotopic model.
33
Some thyroid cancer cell lines were completely resistant
to lexatumumab-induced apoptosis, whereas others
showed intermediate sensitivity. 8505c cells were com-
pletely resistant to lexatumumab-induced apoptosis (4.9±0.9%)
even at 1000ng/ml (Figure 3a), and there was no caspase
cascade activation and no apoptotic cells on TUNEL staining
(Supplementary Figure S1). One other ATC cell line, SW1736
(BRAF
V600E) showed reduced sensitivity to lexatumumab-
induced apoptosis (23.7% cell death, Po0.05) with some
intermediate activation of the extrinsic and intrinsic pathway
caspases (Figure 4a). Given a high background in annexinV-PE
staining in the SW1736 cell line, the MTS assay was used for
determining cell viability in this particular cell line (Figure 3b).
Baseline expression of pro- and anti- apoptotic proteins
was different among sensitive and resistant thyroid
cancer cell lines and was altered with lexatumumab
treatment. The baseline expression of pro- and anti-apopto-
tic proteins was analyzed in detail. Generally in the cell lines
that responded with high or intermediate rates of apoptosis to
the lexatumumab (HTh7, TPC-1, BCPAP and SW1736), the
baseline expression of the pro-apoptotic protein, Bax, was
high resulting in a high Bax to Bcl-xL ratio. The resistant 8505c
cells, however, expressed low Bax and high Bcl-xL protein
levels, resulting in a low Bax/Bcl-xL ratio (Figure 3c).
The two sensitive cell lines, HTh7 and TPC-1, had high
baseline pAkt levels, which rapidly went down with lexatumu-
mab treatment (result not shown), whereas the two cell lines,
8505c and SW1736, had with high pAkt level that increased
further with lexatumumab treatment (Figures 3a and b).
BCPAP had low levels of pAkt that remained low even after
lexatumumab treatment.
Figure 1 Lexatumumab induced apoptosis in various thyroid cancer cell lines. (a) TPC-1, BCPAP, HTh-7 and 8505c human thyroid cancer cell lines were treated with
lexatumumab (1000ng/ml) for 24h. The apoptotic cell population was assayed by annexinV-PE staining and represented as mean±S.D. of three individual experiments.
Three cell lines were highly sensitive to lexatumumab-induced cell death versus untreated control, TPC-1 (98.6.1±1.0%, Po0.001), HTh-7 (82.9±15.5%, Po0.001) and
BCPAP(82.6±22.3%,Po0.01).HCT116,acoloncancercellline,wasusedasapositivecontrolandhada38.9±9.2%,Po0.01apoptoticresponse.8505cATCcellswere
completelyresistant toapoptosis(4.9±0.9%,P40.05).(b) IC50valuesfor lexatumumab were determined usingMTSassayfor eachcellline; TPC-1 was themostsensitive
at 194ng/ml, HTh-7 (220.4ng/ml) and BCPAP (401.5ng/ml). (c) Phase-contrast microscopy showed that lexatumumab treated TPC-1, BCPAP and HTh-7 cells had a
rounded/apoptotic morphology and were positive for TUNEL staining. (d) TPC-1, BCPAP and HTh-7 cells treated with lexatumumab (100ng/ml and 1000ng/ml) for 8h
showed caspase 8, 9, 3 and PARP cleavage. cFLIP and TRAIL-R2 decreased in the lexatumumab treatment groups in all the three cell lines. b-actin was used for loading
control. (**Po0.001 versus control)
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Cell Death and DiseaseHigh pAkt levels contribute to resistance to apoptosis in
the SW1736 cell line with intermediate sensitivity to
lexatumumab, and apoptosis can be enhanced by
inhibition of the PI3K pathway. Given the importance of
pAkt in contributing to TRAIL resistance in other
malignancies,
30,34 we hypothesized that the high baseline
pAkt and the further increased levels with lexatumumab
treatment contributed to the SW1736 cells’ intermediate
sensitivity to this drug. While lexatumumab alone triggered a
23% cell death rate, addition of the PI3K/pAkt inhibitor,
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Figure 2 Lexatumumabinhibitedtumor growth in a BCPAPorthotopicthyroidcancer model. OnemillionBCPAPhuman papillarythyroidcancer cellswere implantedinto
theleftthyroidoftheSCIDmouse.(a)Threeweekspostimplantation,mice(n¼6)wereinjectedtwiceweeklywithlexatumumab(10mg/kgbodyweight)I.V.orsaline(n¼6)
for 4 weeks. (b) Lexatumumab treatment resulted in a 67.4% reduction in tumor growth when compared with control (204±42.5 to 66.5±26.7mm
3, Po0.001).
(c) Orthotopic tumors treated with lexatumumab showed less aggressive histology on H&E but maintained strong staining for TTF-1 and showed signiﬁcantly higher
percentage of apoptotic cells by TUNEL (14.59±2.16% versus 2.47±0.6%, Po0.001) and cleaved caspse-3 staining, compared with controls. A representative of the cells
undergoing apoptosis (TUNEL-positive cells and cells showing cleaved caspase) was indicated by the arrows in the ﬁgure. (**Po0.001 versus control)
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Cell Death and DiseaseLY294002 (50mM), resulted in a 83.7% cell death (Po0.001;
Figure 3b), with the cells showing cleavage of extrinsic and
intrinsic caspases 8/9/3, PARP and the associated Bid
protein (Figures 4a and b) even as early as 8h of treatment.
Lowering pAkt levels caused an increase in both the L&S
forms of the pro-apoptotic protein Bim, which has been
important for initiating TRAIL-induced apoptosis (Figure 4b).
The completely resistant 8505c ATC cell line can be
triggered to undergo apoptosis by inhibiting two
important cell survival pathways. The proliferation of
the ATC cell line 8505c is dramatically affected by the
BRAF
V600E inhibitor PLX4720 both in vitro and in vivo,
12,35
yet ultimately PLX4720 treatment does not cause apopto-
sis. This cell line is also completely resistant to direct
induction of apoptosis with lexatumumab (Figure 3a). As the
baseline pAkt level is already very high and further
increases with either lexatumumab or PLX4720 (10mM)
treatment, similar to what we saw in the SW1736 cell line,
we wanted to test whether the suppression of pAkt alone
would trigger apoptosis. Furthermore, given previous
studies emphasizing the crosstalk between the MAPK and
PI3K cell survival pathways in promoting resistance to
apoptosis,
31,36,37 we chose to study whether dual targeting
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Figure 3 Further inhibition of the PI3K and MAPK pathways sensitized ATC cell lines, 8505c (BRAF
V600E/ ) and SW1736 (BRAF
V600E/wt) to lexatumumab induced
apoptosis.8505cand SW1736ATC cellsweretreatedwithlexatumumab,LY294002,PLX4720eitheraloneor in combinationasindicatedintheFigurefor 48h.At theend of
the treatment, the percentage of cells undergoing apoptosis were assessed using annexinV-PE staining in 8505c cells (n¼3), whereas the percentages of dead cells were
determined using MTS assay for SW1736 cells (n¼3). (a) In the resistant 8505c cells, no single agent induced a signiﬁcant apoptosis. Treatment with the combination of
LY294002 (50mM) and lexatumumab (1000ng/ml) resulted in a signiﬁcant apoptoticcell death (33.1±13.2%,Po0.01 versus control). However,the three drug combination
of lexatumumab, LY294002 and PLX4720 was most effective with an apoptotic cell population of 72.1±3.2% (Po0.001 versus control). Western blot at 8h of treatment
showed the effective inhibition of pAkt and phospho-ERK by LY294002 and PLX4720, respectively. (b) Treatment of the intermediately sensitive SW1736 cells with the
combinationofLY294002(50mM)andlexatumumab(1000ng/ml)resultedinaveryeffectivecelldeathat83.7±5.6%,Po0.001.Westernblotshowedtheeffectiveinhibition
of pAkt by LY294002. (c) Comparison of baseline expression of various pro- and anti-apoptotic proteins showed that the resistant 8505 cells had a low Bax to Bcl-xL ratio
compared with the other lexatumumab-sensitive thyroid cell lines (BCPAP, TPC-1 and HTh7). (*Po0.01 and **Po0.001 versus control)
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Cell Death and Diseaseof these pathways could overcome the severe resistance
that 8505c cells have to lexatumumab-induced apoptosis.
Therefore, three drugs were used singly or in combination
to test our hypothesis: the MAPK/BRAF
V600E inhibitor,
PLX4720 (10mM), PI3K/pAkt inhibitor, LY294002 (50mM),
and lexatumumab.
No drug alone induced apoptosis in 8505c cells with the
percentage of apoptotic cells ranging from 4.9±0.9%
(lexatumumab) to 5.5±1.5% (PLX4720 (10mM)). Dual inhibi-
tion with the MAPK and PI3K inhibitors (PLX4720 and
LY294002) without the apoptotic agent also did not boost
apoptosis (5.9±4.2%; Figure 3a).
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Figure 4 Triple-drug (LY294002, PLX4720 and lexatumumab) and dual-drug combinations (LY294002 and lexatumumab) triggered the intrinsic and extrinsic apoptotic
pathwaysin 8505c and SW1736cells. 8505c and SW1736cells were treated for 8h with drug combinations as indicatedin theﬁgure and analyzedfor pro- and anti-apoptotic
proteinsbywesternblot.(a)Treatmentwithtriple-drugcombinationin8505candthedualcombinationinSW1736resultedincleavageofcaspase8/9/3andPARP.(b)Triple-
drugcombinationresultedintheincreaseinpro-apoptoticproteinsBad,Bim,BaxandBakin8505ccells.Dualinhibitorcombination,ontheotherhand,resultedinanincrease
in BimL&S formsin SW1736cells. (c) Triple-drugcombinationsigniﬁcantly decreasedthe anti-apoptotic proteins Bcl-xLand Mcl-1in 8505c cellsat 8h of treatment.(d) cFLIP
decreased in both the dual and triple-drug combinational treatments of 8505c cells. (e) Treatment of 8505c cells at different time points up to 48h with the triple-drug
combination also showed a signiﬁcant decrease in anti- apoptotic proteins, Bcl-xL, Mcl-1, cFlip and an increase in pro-apoptotic proteins, Bax and Bim isoforms. b-Actin was
used as loading control
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Cell Death and DiseaseHowever, combining lexatumumab with the inhibitors of
either of the two pathways did result in increased apoptosis.
Dual combination of lexatumumab and LY294002 increased
apoptosis to 33.1±13.2%, Po0.01 (Figure 3a), whereas the
dual combination with PLX4720 caused a moderate increase
in apoptosis to 20.9±3.6%, Po0.01. Combining all three
drugs together, however, resulted in dramatic apoptosis
(72.1±3.2%, Po0.001; Figure 3a) and strong TUNEL
staining (Supplementary Figure S1). Dosing curves were
used to calculate optimal dosage and showed that combining
these three drugs together allowed a much lower dose of
lexatumumab (IC50 of 200ng/ml, data not shown) to be
effective at inducing apoptosis with maximal apoptosis at
500ng/ml (Supplementary Figure S2).
Analysis of the pro- and anti-apoptotic pathway proteins in
8505c cells treated with the combination of all three drugs:
PLX4720 (10mM), LY294002 (50mM) and lexatumumab
(1000ng/ml) in 8505c cells showed (Figure 4):
(a) Activation of all extrinsic and intrinsic pathways with
signiﬁcant cleavage of caspase-8/-9/-3 and PARP
(Figure 4a).
(b) Activation of the pro-apoptotic proteins: cleavage of Bid
(indicated by the decrease of pro-Bid protein; Figure 4b) and
increased expression of Bad, Bak, Bim (BimL and BimS) and
Bax (Figure 4b). The Bim expression was highest after 24h of
treatment, whereas Bax increased in expression after 1h and
then remained stably elevated till 24h (Figure 4e).
(c) Dramatic decrease in anti-apoptotic proteins – Bcl-xL,
Mcl-1and c-FLIP – (Figures 4c and d) were reduced with
treatment, even as early as after 2h of treatment and
remained so up to 48h (Figure 4e).
(d) TRAIL-R2 expression, on the other hand, increased
immediately after the treatment for a short time and then
progressively decreased by 48h (Figure 4e).
Bcl-xL has a signiﬁcant role in the resistance of 8505c
cells to induction of apoptosis. Our results with the three
drug combination conﬁrms the work of other authors in
various other malignant lines, indicating that decreased
expression of anti-apoptotic protein Bcl-xL is critical in
initiation and maintenance of a robust apoptotic response
to TRAIL.
22,38–41 The 8505c cells started with a very high
baseline Bcl-xL protein level, which was reduced signiﬁcantly
after transfection with Bcl-xL siRNA for 48h (Figure 5a).
Subsequent treatment of these cells with lexatumumab
(1000ng/ml) resulted in 52.3% apoptosis as measured by
annexinV-PE staining as well as caspase 3 and PARP
cleavages compared with lexatumumab controls (3.4%
apoptosis) or scrambled siRNA (8.4%; Figures 5b and c).
Dual inhibition of pAkt and MAPK pathways increases
the lexatumumab-induced apoptosis in 8505c orthotopic
thyroid model. On the basis of our in vitro results, we
predicted that the three drug combination would result in
tumor apoptosis in an 8505c thyroid orthotopic model of
aggressive thyroid cancer with wide spread lung metastases.
Treatment was initiated 2 weeks post-orthotopic implantation
of 8505c–GFP cells and continued for 2 weeks with either
lexatumumab (5mg/kg body weight, IV twice a week),
PLX4720 (417mg/kg chow diet), LY294002 (50mg/kg body
weight, IP twice a week) or a combination of all three drugs
(Figure 6a). Controls received normal chow and saline.
Results showed that 4 weeks post-tumor implantation,
treatment with lexatumumab alone (76.8±15.2mm
3) and
LY294002 alone (72.5±12.0mm
3) did not result in a
statistically signiﬁcant decrease in tumor volume or metas-
tasisascomparedwithcontrol(91.2±20.6mm
3;Figures6a–c).
We conﬁrmed that PLX4720 alone reduced primary tumor
volume by 95% and completely treated the lung metastases
compared with controls. PLX4720 treatment in vivo only
resulted in o4% of cells showing cleaved caspase-3 by IHC,
which was not signiﬁcantly increased compared with controls.
The three drug combination resulted in 99% reduction in
primary tumor volume, complete disappearance of lung
metastases and elevated cleaved caspase 3 levels to
14±2%. All the tumors in the control group and the treated
groups stained positive for TTF-1 (Figure 6c). It seemed that,
while the reduction in the primary tumor volume was
statistically no different between PLX4720 alone and the
three drug combination, given the dramatic tumor reductions
in both scenarios, apoptosis was clearly only triggered with
the three drug combination.
Human PTC expression proﬁling of apoptotic genes
show a pattern of potential sensitivity to lexatumumab.
If TRAIL-based therapies are to be attempted in patients with
thyroid cancer, it is important to understand the basal
expression of various apoptotic and death receptor gene
expression proﬁles in thyroid cancer patient samples,
compared with normal thyroid samples. Using microarray
genomic data from PTC and normal thyroid samples by
Giordano et al.,
42 we analyzed 75 genes related to apoptosis:
two of these decreased, whereas seven increased in
expression by at least twofold (Po0.001). Expression
proﬁles for ﬁve of these genes were then conﬁrmed by RT-
PCR in a cohort of 10 human PTCs and four matched normal
thyroid tissues. Those that showed more than a twofold
difference in relative values of comparisons (Po0.05) were
considered differentially expressed. Four of the ﬁve
genes had higher relative mRNA expressions in PTC
samples compared with the matched normal thyroids –
TRAIL-R2 (B3.2±1.4-fold change, Po0.05; Figure 7a),
Bax (B3.0±2.5-fold change, Pr0.05; Figure 7b), Bcl-xL
(B2.7±0.5-fold change, Po0.01; Figure 7c) and Bid
(B8.2±2.5-fold change, Po0.001; Figure 7e). In contrast,
Bim (2.9±0.92-fold change, Po0.01; Figure 7d) showed a
signiﬁcant decrease in levels between the PTC patient
tumors and normal thyroids. This pattern is similar to that
seen in the sensitive BCPAP cell line.
Discussion
Aggressive thyroid cancers remain resistant to traditional
chemotherapeutic agents. Novel targeted therapies are being
tested in the preclinical and clinical setting for the last 5 years.
Effort has been mostly focused on multikinase inhibitors such
as sorafenib or targeting the BRAF or MEK pathways. Agents
triggering apoptosis have not been well studied in thyroid
cancer.
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Cell Death and DiseaseWe report here for the ﬁrst time the efﬁcacy of the
pro-apoptotic TRAIL-receptor 2 agonist, lexatumumab, in
inducing apoptosis in a variety of representative thyroid cancer
cells with well-deﬁned mutations that include BRAF
V600E
(BCPAP, 8505c, SW1736), NRAS
Q61R (HTh-7) and RET/
PTC (TPC-1). We observed a range of apoptotic responses to
lexatumumab, with some being exquisitely sensitive (TPC-1,
HTh-7 and BCPAP), whereas others were moderately or
completely resistant (SW1736 and 8505c). Interestingly, the
mutational status alone did not show a direct correlation to
lexatumumab sensitivity. When exposed to lexatumumab,
the sensitive cell lines were able to efﬁciently and rapidly
activate both extrinsic and intrinsic apoptotic pathways. As
there was a strong apoptotic response ranging from 83 to 99%
in the three sensitive cell lines, we tested the in vivo efﬁcacy of
this novel antibody in an orthotopic animal model of thyroid
cancerusingoneofthesensitivecelllines,BCPAP.Ourresults
showed that lexatumumab treatment alone induced apoptosis
in vivo, which resulted in effective tumor shrinkage of 67%,
indicating the potential utility of this agent in some patients with
papillary or ATCs. Furthermore, expression proﬁling of ﬁve
genes known to be important in regulating the apoptotic
response to lexatumumab showed that all 10 PTC samples
directly from patients had proﬁles that were similar to the
BCPAP PTC cell line, which we have shown here to be
exquisitely sensitive to TRAIL-induced apoptosis.
Not surprisingly, the most aggressive ATC cell line we
studied, 8505c, showed remarkable resistance to apoptosis
with o5% of cells undergoing apoptosis even when exposed
to high doses of lexatumumab. These data are consistent
with our previous studies showing that this cell line is
generally resistant to apoptosis when treated with other
agents.
22,23,40 We were able to induce apoptosis in this
resistantcelllinebycombininglexatumumabwithaPI3K/Akt
inhibitor LY294002 and a BRAF
V600E inhibitor PLX4720. Our
combinatorial strategy that was guided by known signaling
pathway and genomic data led to rapid and sustained
apoptosis in vitro and in vivo. Although PLX4720 alone
effectively reduced the tumor volume and the lung metas-
tasis, it failed to induce apoptosis in the tumor cells in vivo.
Development of resistance to PLX4720 is a major limitation
when it comes to efﬁcacy in treating patients as recurrent
tumor growth occurs from the few remaining cells that have
notundergoneapoptosis.Thisstudypointstotheutilityofthe
three-drug combination in inducing apoptosis in the 8505c
orthotopic tumors along with the rapid tumor shrinkage and
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Figure 5 Knockdown of Bcl-xL sensitized 8505c cells to lexatumumab-induced apoptosis. Cells were transfected with 50-nM Bcl-xL or control siRNA for 48h and then
treated with 1000ng/ml of lexatumumab for another 24h. (a) Bcl-xL protein level signiﬁcantly decreased after 48h of transfection with Bcl-xL siRNA. b-Actin served as a
loading control. (b) Treatment of Bcl-xL knockdown cells with lexatumumab showed a signiﬁcant increase in cell death (52.3%, Po0.01 versus control) as measured by
annexinV–PE staining; the treated cells showed the cleavage of caspase-3 and PARP (c)
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Cell Death and Diseasereduction of lung metastasis. This study among others can
lead to better long-term outcomes. Our data showed that two
critical elements had a role in the marked resistance to
apoptosis in this cell line (Figure 8b). The 8505c cells had
both a very high baseline expression of Bcl-xL and a low
expression of Bax (low Bax/Bcl-xL ratio) and when exposed
to lexatumumab treatment mounted a remarkable increase
in pAkt levels. As pAkt is a well-known anti-apoptotic protein,
a sudden increase in pAkt when exposed to the apoptotic
agent is in sharp contrast to the sensitive cell lines, which
show suppression of pAkt levels. Inhibition of pAkt by
LY294002 or knockdown of Bax/Bcl-xL protein ratio
alone did somewhat increase the apoptotic response
to 30%; however, only when the three-drug combination
was used were these cells able to mount an apoptotic
response up to 68%.
The ‘crosstalk’ between apoptotic and various kinase
pathways is just starting to be studied in other malignancies.
In colorectal cancer, resistance to apoptosis is thought to be
due to dual mutations in the PI3 and MAP Kinase pathways
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Figure 6 Treatment with the triple-drug combination (LY294002, PLX4720 and lexatumumab) increased apoptosis in 8505c-originated orthotopic thyroid tumors. One
million 8505c cells were implanted into the left thyroid of the SCID mouse. (a) Two weeks post implantation, the mice (six mice/group) were treated for another 2 weeks with
lexatumumab (5mg/kg body weight, I.V twice every week), PLX4720 (417mg/kg chow diet), LY294002 (50mg/kg body weight, I.P twice every week) separately as single
agents,whereasonegroupreceivedthetriplecombinationdrugs.Controlgroupofmicereceivedsalineandfedonthenormalchow.Treatmentwithsingledrugagentsdidnot
signiﬁcantly decrease tumor volume compared with control (91.2±20.6mm
3): lexatumumab (76.8±15.2mm
3) and LY294002 (72.5±12.0mm
3). Mice receiving either
PLX4720 alone or the triple-drug combination showed dramatic decreases in tumor volume (4.6±3.1mm
3). (**Po0.001 versus control). (b) GFP imaging of the thyroid
orthotopic tumors and lung conﬁrmed reductions in the primary tumor and metastasis. (c) All tumors showed aggressive histology and expressed TTF-1. Triple-drug therapy
signiﬁcantly increased the levels of apoptotic cells in the tumor, as measured by cleaved caspase-3 IHC staining compared with single agent therapy with PLX4720 (14±2%
versus o4%)
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H1047 and BRAF
V600E), which cause high levels of
pAkt, thus blocking TRAIL-induced apoptosis. In melanoma
and non-small cell lung carcinoma, high basal or induced pAkt
protein levels conferred resistance to apoptosis by MEK
inhibitors.
31,43,44 Here we have shown that in thyroid cancer,
resistance to apoptosis follows a similar pattern. The ATC cell
line 8505c demonstrates a remarkable decrease in prolifera-
tionwhenexposedtoBRAF
V600EinhibitorPLX4720;however,
unfortunately there is a simultaneous detrimental further
increase in pAkt levels that essentially prevents the initiation
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Figure 7 Relative real-time RT-PCR of Bax, Bcl-xL, Bim, Bid and TRAIL-R2 in patient PTC samples (n¼10) compared with matched normal thyroid tissue (NT; n¼4).
(a)TRAIL-R2wasupregulatedB3.2±1.4-fold(Po0.05)inPTCsversusnormalthyroid.(b)BaxwasupregulatedB3.0±2.5-fold(Pr0.05)inPTCsversusnormalthyroid.
(c)Bcl-xLwasupregulatedB2.7±0.5-fold(Po0.01)inPTCsversusnormalthyroid.(d)BimwasdownregulatedB2.9±0.92-fold(Po0.01)inPTCsversusnormalthyroid.
(e) Bid was upregulated B8.2±2.5-fold (Po0.01) in PTCs versus normal thyroid. (*Po0.01 and **Po0.001)
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Cell Death and Diseaseof apoptosis. Our three-drug combination is likely effective
due to effects on multiple fronts. Most importantly, the
inhibition of both pAkt and the MAPK pathway controls
the regulatory increase in alternative pathways caused by
theother’snegatedpathway.Inaddition,beneﬁcialalterations
in the ratios of pro-apoptotic proteins, Bax and Bak, protein
expressionsandtheanti-apoptotic proteins,Bcl-xL,Mcl-1and
cFLIP, favors overcoming the resistance to TRAIL.
45,46
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Cell Death and DiseaseFinally, elevations in all three isoforms of Bim contribute to a
higher apoptotic response.
47,48
Interestingly, we also found that one ATC cell line had an
intermediate sensitivity to lexatumumab – SW1736, showing
a 24% cell death response. This cell line already has a high
Bax/Bcl-xL ratio similar to all the sensitive cell lines; therefore,
we hypothesized that the resistance to apoptosis was likely
due to an increase in pAkt when exposed to lexatumumab.
Dual-drug combination of a pAkt inhibitor along with lexatu-
mumab triggered increased cell death up to 84%, indicating
the importance of inhibition of the pAkt pathway alone in this
intermediately sensitive cell line.
We have shown here that some thyroid cancer cell lines are
sensitive to apoptotic agents and these agents should be tried
clinically in appropriate patients. Appropriate patients may
include those with no known mutations, high levels of TRAIL-
R2 receptor and a high Bax to Bcl-xL ratio, as these patients
have elements to suggest that their tumors will be sensitive to
apoptotic agents alone. Patients with either activating muta-
tionsinthePI3KorMAPKpathwaysand/oralowbaselineBax
to Bcl-XL ratio may need a combination of pro-apoptotic
agents such as lexatumumab with kinase inhibitors to show
efﬁcacy. Further studies in genetically engineered models of
aggressive thyroid cancer in mice, which harbor additional
mutations such as p53 and BRAF,
49,50 will undoubtedly shed
light on the true efﬁcacy of a combinatorial strategy.
Materials and methods
Cell culture, antibodies and reagents. Reagents included the following:
lexatumumab (Human Genome Sciences, GlaxoSmithKline, Philadelphia, PA,
USA), LY294002 (Cell Signaling Technology, Danvers, MA, USA) and PLX4720
(Plexxikon, Berkeley, CA, USA). Antibodies – b-actin, phospho-p44/42 MAPK
(ERK1/2) (Thr202/Tyr204) (phospho-ERK), p44/42 MAPK (ERK1/2) (Total ERK),
total Akt, phospho-Akt (Ser
473), caspases 3,8,9, cleaved caspase-3, PARP,
c-FLIP, TRAIL-R2, Bcl2, Bcl-xL, Mcl-1, Bim, Bid, Bax, Bad, Bak were purchased
from Cell Signaling Technology.
ATC cell lines – 8505c (BRAF
V600E/ ), SW1736 (BRAF
V600E/wt), HTh-7
(NRAS
Q61R); PTC cell lines – BCPAP (BRAF
V600E/wt), TPC-1 (RET/PTC-1); and
normalthyroidcellline–HToriweregrowninRPMI1640mediumwith10%FBSand
Penicillin (100units/ml)/streptomycin (100mg/ml) (Gibco, Grand Island, NY, USA).
Apoptosis assays and western blots. Treatment was carried out at 60–
70% conﬂuency. BCPAP, HTh-7 and TPC-1 cells were treated with lexatumumab
(1000ng/ml) for 24h, whereas 8505c and SW1736 cells received treatment with
lexatumumab alone or in combination with LY294002 (50mM) and PLX4720
(10mM) for 48h. The percent of apoptotic cells was assayed by ﬂow cytometry
(BD Sorp 8 Laser LSR II (BD Biosciences, San Jose, CA, USA) using
annexinV–PE Apoptosis Detection Kit (BD Biosciences). Flow cytometry data were
analyzed using FlowJo (Tree Star Inc., Ashland, OR, USA).
For determining the IC50 and response curves of lexatumumab, 10000 cells
were treated with a wide range of lexatumumab concentrations for 72h and cell
viability was tested using CellTiter96 Aqueous One Solution Reagent for the MTS
assay (Promega, Madison, WI, USA).
For terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) assay, cells were ﬁxed with 1% paraformaldehyde in cold PBS and
processedusingtheAPO-BrdUTUNELkit(Invitrogen,GrandIsland,NY,USA),and
apoptotic cells were counted using ﬂuorescence.
For western blot analysis, all the drug treatments were carried out for 8h at 60–
70%cellconﬂuency.At theendof thetreatment,thecellswerelysed on ice inRIPA
buffer containing protease and phosphatase inhibitor cocktail (Thermo Scientiﬁc,
Rockford,IL,USA).Westernblotassaywasperformedusingstandardprocedure.
10
siRNA knockdown. A total of 1 10
5 8505c cells were transfected with
either 50nM of Bcl-xL siRNA (siGENOME SMARTpool) or scrambled siRNA
(Dharmacon/Thermo Fisher Scientiﬁc Inc.), using Dharmafect2 and incubated for
48h to achieve Bcl-xL protein knockdown. Cells were then treated with
lexatumumab (1000ng/ml) for 24h and assayed for apoptosis.
Real-time PCR. Real-time PCR was performed and analyzed using
Lightcycler 96 (Roche) qPCR machine and its software, normalized to GAPDH
expression as described previously.
10 Primer sequences include: TRAIL-R2
(forward): 50-ACCACGACCAGAAACACAG-30 and (reverse): 50-CATTCGATGTCA
CTCCAGGG-30; Bcl-xL (forward): 50-GTGGAAAGCGTAGACAAGGAG-30 and
(reverse): 50-CTGCATTGTTCCCATAGAGTTC-30; Bax (forward): 50-AGTAACATG
GAGCTGCAGAG-30 and (reverse): 50-AGTAGAAAAGGGCGACAACC-30; Bid
(forward): 50-ATTAACCAGAACCTACGCACC-30 and (reverse): 50-TGACCACATC
GAGCTTTAGC-30; Bim (forward): 50-TCGGACTGAGAAACGCAAG-30 and
(reverse): 50-CTCGGTCACACTCAGAACTTAC-30.
Orthotopic thyroid cancer model and pathologic analysis. All
animal work was conducted at the Massachusetts General Hospital in accordance
with the federal, local and institutional guidelines. For orthotopic tumor
implantations, 10-week-old female SCID mice were injected with 10
6 tumor cells
as previously described:
32 12 animals had BCPAP cells implanted (6/group), and
40 animals had 8505c-GFP cells injected (8/group).
32 At the end of treatment, the
mice were killed and the tumor volume was calculated as (p/6) length 
width height. Tumor growth inhibition (TGI) was determined using: TGI¼(1 
treatment/control) 100. GFP imaging was performed using multispectral
ﬂuorescence scanner (CRi Maestro 500, CRi Inc.). Tumors were collected in
10% formalin for H&E, TUNEL, TTF-1 and cleaved caspase-3. In case of mice
injected with 8505c–GFP cells, the tumors were collected at the end of 1-week
treatment for the IHC analysis.
Statistical analysis. Statistical analysis was carried out using Microsoft
Excel (Microsoft, Redmond, VA, USA) and GraphPad Prism (GraphPad, La Jolla,
CA, USA). All experiments were performed at least three times, and the results
were expressed as mean± S.D. of the individual experiments. Results were
compared using the unpaired, two-tailed Student’s t-test; P-values of o0.05 were
considered signiﬁcant (*Po0.01, **Po0.001).
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